Joseph Schlessinger
Yale University · 701 works · 123,779 citations · h-index 173
Top works
- Signal transduction by receptors with tyrosine kinase activity
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
- Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells
- The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
- Cell Signaling by Receptor Tyrosine Kinases
- Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.
- Mobility measurement by analysis of fluorescence photobleaching recovery kinetics
- EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
- Growth factor signaling by receptor tyrosine kinases
- Cell Signaling by Receptor Tyrosine Kinases
- Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation.
- Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
- Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases
- Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases
- Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma